Composition and medical product for reducing body weight and body fat, and use of said product

• US 10,537,548 B2
• Filed: 03/27/2018
• Issued: 01/21/2020
• Est. Priority Date: 08/28/2014
• Status: Active Grant

• Current Assignee: Caliway Biopharmaceuticals Co., Ltd.
• Original Assignee: Caliway Biopharmaceuticals Co., Ltd.
• Inventors: Ling, Yu-Fang
• Primary Examiner(s): Kosson, Rosanne
• Application Number:
  US15/936,695
• Publication Number:
  US 20180333388A1
• Time in Patent Office: 665 Days
• CPC Class Codes: A23F 3/16 Tea extraction; Tea extracts; Treating tea extract; Making instant tea
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/328 having effect on glycaemic control and diabetes
• CPC Class Codes: A23V 2200/332 Promoters of weight control and weight loss
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
• CPC Class Codes: A61K 36/82 Theaceae (Tea family), e.g. camellia
• CPC Class Codes: A61K 36/9066 Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention discloses a composition and its pharmaceutical composition for reducing body weight and body fat, and a use of said product The composition comprises epigallocatechin gallate, curcumin, and an excipient, wherein the excipient comprises at least one of glyceryl dibehenate, polyoxyethylene stearates, polysorbate 80 mixture, vitamin E polyethylene glycol succinate, glyceryl monostearate, and oleoyl polyoxyl-6 glycerides, or a combination thereof; the polysorbate 80 mixture comprises polysorbate 80 and magnesium aluminometasilicate. In animal testing where obesity is induced either prior to or during testing, use of the composition of the present invention leads to a significant reduction of body weight and body fat.

Claims

1. A composition for reducing body weight or body fat, comprising:

(a) an excipient; and

(b) an active ingredient composition for reducing body weight or body fat, wherein the active ingredient composition for reducing body weight or body fat comprises epigallocatechin gallate (EGCG) and curcumin; and

wherein the excipient is selected from the group consisting of glyceryl dibehenate, polyoxyethylene stearates, a polysorbate 80 mixture, wherein the polysorbate 80 mixture comprises polysorbate 80 and aluminometasilicate, vitamin E polyethylene glycol succinate, oleoyl polyoxyl-6 glycerides, and a combination thereof.

2. The composition for reducing body weight or body fat according to claim 1, further comprising at least one of glyceryl palmitostearate, polysorbate 20, poloxamer, and polyethylene glycols, or a combination thereof.

3. The composition for reducing body weight or body fat according to claim 1, further comprising piperine.

4. The composition for reducing body weight or body fat according to claim 1, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 0.1-20% based on the total weight of said composition for reducing body weight or body fat;

or, the weight percentage of said polysorbate 80 mixture is 0.5-20% based on the total weight of said composition for reducing body weight or body fat;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.005-6.7% based on the total weight of said composition for reducing body weight or body fat.

5. The composition for reducing body weight or body fat according to claim 1, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 1-15% based on the total weight of said composition for reducing body weight or body fat;

or, the weight percentage of said polysorbate 80 mixture is 1-15% based on the total weight of said composition for reducing body weight or body fat;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.01-3.3% based on the total weight of said composition for reducing body weight or body fat.

6. The composition for reducing body weight or body fat according to claim 1, wherein said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 1-10% based on the total weight of said composition for reducing body weight or body fat;

or, the weight percentage of said polysorbate 80 mixture is 3-10% based on the total weight of said composition for reducing body weight or body fat;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.05-1% based on the total weight of said composition for reducing body weight or body fat.

7. The composition for reducing body weight or body fat according to claim 1, wherein said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (32) stearate is 5.3-26.7;

or, the value of the ratio of the weight of said curcumin to the weight of said polysorbate 80 mixture is 2-8.9;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (40) stearate is 40-533.3;

or, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (32) stearate is 9.5-47.5;

or, the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polysorbate 80 mixture is 3.6-15.8;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (40) stearate is 71.3-950.

8. The composition for reducing body weight or body fat according to claim 1, further comprising at least one of mannitol, microcrystalline celluloses, sodium dodecyl sulfate (SDS), and cross-linked sodium carboxymethyl cellulose, croscarmellose sodium or a combination thereof.

9. The composition for reducing body weight or body fat according to claim 1, wherein, the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.32;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-75.8%, and the weight percentage of said curcumin is 24.2-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

10. The composition for reducing body weight or body fat according to claim 1, wherein, the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.4;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-71.4%, and the weight percentage of said curcumin is 28.6-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

11. The composition for reducing body weight or body fat according to claim 1, wherein said active ingredient composition for reducing body weight or body fat further comprises resveratrol.

12. A method for reducing body weight or body fat of an individual, comprising administering a therapeutically effective amount of the composition of claim 1 to an individual.

13. The method according to claim 12, wherein said composition further comprises at least one of glyceryl palmitostearate, polysorbate 20, poloxamer, and polyethylene glycols, or a combination thereof.

14. The method according to claim 12, wherein said composition further comprises piperine.

15. The method according to claim 12, wherein said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 0.1-20% based on the total weight of said composition;

or, the weight percentage of said polysorbate 80 mixture is 0.5-20% based on the total weight of said composition;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.005-6.7% based on the total weight of said composition.

16. The method according to claim 12, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 1-15% based on the total weight of said composition;

or, the weight percentage of said polysorbate 80 mixture is 1-15% based on the total weight of said composition;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.01-3.33% based on the total weight of said composition.

17. The method according to claim 12, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 1-10% based on the total weight of said composition;

or, the weight percentage of said polysorbate 80 mixture is 3-10% based on the total weight of said composition;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.05-1% based on the total weight of said composition.

18. The method according to claim 12, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (32) stearate is 5.3-26.7;

or, the value of the ratio of the weight of said curcumin to the weight of said polysorbate 80 mixture is 2-8.9;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (40) stearate is 40-533.3;

or, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (32) stearate is 9.5-47.5;

or, the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polysorbate 80 mixture is 3.6-15.8;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (40) stearate is 71.3-950.

19. The method according to claim 12, wherein said composition further comprises at least one of mannitol, microcrystalline celluloses, sodium dodecyl sulfate (SDS), and cross-linked sodium carboxymethyl celluloses, croscarmellose sodium or a combination thereof.

20. The method according to claim 12, wherein the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.32;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-75.8%, and the weight percentage of said curcumin is 24.2-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

21. The method according to claim 12, wherein the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.4;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-71.4%, and the weight percentage of said curcumin is 28.6-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

22. The method according to claim 12, wherein said active ingredient composition for reducing body weight or body fat further comprises resveratrol.

23. The method according to claim 12, wherein said composition is administered orally to said individual.

24. The method according to claim 12, wherein said individual is an individual of normal body weight, an overweight individual, an obese individual, an individual with fatty liver, or an individual with non-alcoholic steatohepatitis (NASH).

25. A method for treating fatty liver or non-alcoholic steatohepatitis, comprising administering to an individual with fatty liver or non-alcoholic steatohepatitis a therapeutically effective amount of the composition of claim 1.

26. The method according to claim 25, wherein said composition further comprises at least one of glyceryl palmitostearate, polysorbate 20, poloxamer, and polyethylene glycols, or a combination thereof.

27. The method according to claim 25, wherein said composition further comprises piperine.

28. The method according to claim 25, wherein said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the weight percentage of said polyoxyethylene (32) stearate is 0.1-20% based on the total weight of said composition;

or, the weight percentage of said polysorbate 80 mixture is 0.5-20% based on the total weight of said composition;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the weight percentage of said polyoxyethylene (40) stearate is 0.005-6.7% based on the total weight of said composition.

29. The method according to claim 25, wherein, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (32) stearate is 5.3-26.7;

or, the value of the ratio of the weight of said curcumin to the weight of said polysorbate 80 mixture is 2-8.9;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said curcumin to the weight of said polyoxyethylene (40) stearate is 40-533.3;

or, said polyoxyethylene stearate is polyoxyethylene (32) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (32) stearate is 9.5-47.5;

or, the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polysorbate 80 mixture is 3.6-15.8;

or, said polyoxyethylene stearate is polyoxyethylene (40) stearate, and the value of the ratio of the weight of said active ingredient composition for reducing body weight or body fat to the weight of said polyoxyethylene (40) stearate is 71.3-950.

30. The method according to claim 25, wherein said composition further comprises at least one of mannitol, microcrystalline celluloses, sodium dodecyl sulfate (SDS), and cross-linked sodium carboxymethyl celluloses, or a combination thereof.

31. The method according to claim 25, wherein the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.32;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-75.8%, and the weight percentage of said curcumin is 24.2-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

32. The method according to claim 25, wherein the value of the ratio of the weight of said curcumin to the weight of said epigallocatechin gallate (EGCG) is 3.2-0.4;

or, the weight percentage of said epigallocatechin gallate (EGCG) is 23.8-71.4%, and the weight percentage of said curcumin is 28.6-76.2%, based on the total weight of said active ingredient composition for reducing body weight or body fat.

33. The method according to claim 25, wherein said composition is administered orally to said individual with fatty liver or non-alcoholic steatohepatitis.